Head to Head Comparison: Viatar CTC Solutions (OTCMKTS:VRTT) versus Inovio Pharmaceuticals (OTCMKTS:INO)

Viatar CTC Solutions (OTCMKTS:VRTT) and Inovio Pharmaceuticals (NASDAQ:INO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Viatar CTC Solutions and Inovio Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viatar CTC Solutions 0 0 0 0 N/A
Inovio Pharmaceuticals 0 0 5 0 3.00

Inovio Pharmaceuticals has a consensus price target of $7.32, suggesting a potential upside of 190.63%. Given Inovio Pharmaceuticals’ higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Viatar CTC Solutions.

Profitability

This table compares Viatar CTC Solutions and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viatar CTC Solutions N/A N/A N/A
Inovio Pharmaceuticals -1,560.70% -142.10% -74.25%

Valuation and Earnings

This table compares Viatar CTC Solutions and Inovio Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Viatar CTC Solutions N/A N/A N/A N/A N/A
Inovio Pharmaceuticals $30.48 million 8.19 -$96.97 million ($1.05) -2.40

Viatar CTC Solutions has higher earnings, but lower revenue than Inovio Pharmaceuticals.

Institutional & Insider Ownership

46.4% of Inovio Pharmaceuticals shares are held by institutional investors. 7.9% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Viatar CTC Solutions has a beta of -0.91, meaning that its share price is 191% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

Summary

Inovio Pharmaceuticals beats Viatar CTC Solutions on 6 of the 9 factors compared between the two stocks.

About Viatar CTC Solutions

Viatar CTC Solutions Inc., a biotechnology company, focuses on developing and marketing cancer molecular diagnostics and cancer therapy products in the United States. Its products include Viatar collection system for molecular analysis that collects and purifies circulating tumor cells (CTCs) for DNA sequencing and other genetic analysis technologies used primarily for research; and Viatar therapeutic oncopheresis system to remove CTCs from a patient's blood as a new cancer therapy for metastatic disease. The company was formerly known as Vizio Medical Devices LLC and changed its name to Viatar CTC Solutions Inc. in February 2014. Viatar CTC Solutions Inc. was founded in 2007 and is headquartered in Lowell, Massachusetts.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Receive News & Ratings for Viatar CTC Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viatar CTC Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News